1. Home
  2. RR vs GYRE Comparison

RR vs GYRE Comparison

Compare RR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Richtech Robotics Inc. Class B

RR

Richtech Robotics Inc. Class B

HOLD

Current Price

$5.45

Market Cap

690.2M

Sector

N/A

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$8.00

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RR
GYRE
Founded
2016
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
690.2M
755.7M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
RR
GYRE
Price
$5.45
$8.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$17.00
AVG Volume (30 Days)
32.2M
77.0K
Earning Date
01-20-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.04
Revenue
$5,045,000.00
$107,265,000.00
Revenue This Year
$147.00
$11.59
Revenue Next Year
$37.21
$26.31
P/E Ratio
N/A
$201.83
Revenue Growth
18.99
2.13
52 Week Low
$1.37
$6.11
52 Week High
$7.43
$13.75

Technical Indicators

Market Signals
Indicator
RR
GYRE
Relative Strength Index (RSI) 68.03 57.06
Support Level $3.81 $7.72
Resistance Level $4.85 $8.38
Average True Range (ATR) 0.52 0.33
MACD 0.12 0.06
Stochastic Oscillator 93.18 76.18

Price Performance

Historical Comparison
RR
GYRE

About RR Richtech Robotics Inc. Class B

Richtech Robotics Inc is a developer of new robotic technologies focused on transforming labor-intensive services in hospitality and other sectors currently experiencing unprecedented labor shortages. The company designs, manufacture and sells robots to restaurants, hotels, senior living centers, casinos, factories, movie theaters and other businesses. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company designs its robots to be friendly, customizable to client environments, and extremely reliable.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: